Annex Advisory Services LLC Has $30.22 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Annex Advisory Services LLC raised its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 13.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 99,190 shares of the company's stock after acquiring an additional 12,045 shares during the quarter. Annex Advisory Services LLC owned about 0.33% of Medpace worth $30,222,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sone Capital Management LLC acquired a new stake in Medpace in the fourth quarter worth $1,318,000. Barclays PLC raised its holdings in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company's stock worth $6,603,000 after purchasing an additional 8,275 shares during the period. Sanctuary Advisors LLC raised its holdings in Medpace by 20.5% in the fourth quarter. Sanctuary Advisors LLC now owns 4,964 shares of the company's stock worth $1,738,000 after purchasing an additional 844 shares during the period. Truist Financial Corp raised its holdings in Medpace by 166.2% in the fourth quarter. Truist Financial Corp now owns 10,277 shares of the company's stock worth $3,414,000 after purchasing an additional 6,417 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in Medpace by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 201,046 shares of the company's stock worth $66,794,000 after purchasing an additional 2,142 shares during the period. 77.98% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MEDP has been the topic of a number of research analyst reports. Truist Financial dropped their price objective on shares of Medpace from $333.00 to $300.00 and set a "hold" rating on the stock in a report on Wednesday, April 23rd. Leerink Partners initiated coverage on shares of Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective on the stock. William Blair restated a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a report on Monday, March 24th. Finally, Mizuho dropped their price objective on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a report on Wednesday, April 9th. Eleven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $349.30.

Medpace Stock Performance

Medpace stock traded down $19.16 during mid-day trading on Thursday, reaching $293.58. The company's stock had a trading volume of 525,582 shares, compared to its average volume of 357,780. The company has a market capitalization of $8.44 billion, a price-to-earnings ratio of 23.24, a price-to-earnings-growth ratio of 3.81 and a beta of 1.55. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $459.77. The business's 50 day simple moving average is $298.32 and its 200 day simple moving average is $324.17.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Monday, April 21st. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The company had revenue of $558.57 million during the quarter, compared to the consensus estimate of $528.38 million. During the same quarter last year, the firm posted $3.20 EPS. As a group, sell-side analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Activity

In related news, Director Fred B. Davenport, Jr. sold 1,712 shares of Medpace stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the sale, the director now owns 2,998 shares of the company's stock, valued at approximately $904,856.36. The trade was a 36.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 20.30% of the company's stock.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.